TITLE

Update of research and management of hepatitis B

AUTHOR(S)
Okanoue, Takeshi; Minami, Masahito
PUB. DATE
February 2006
SOURCE
Journal of Gastroenterology;Feb2006, Vol. 41 Issue 2, p107
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on developments on research and management of hepatitis B. Nucleoside analogues and long-acting interferon were introduced to treat chronic hepatitis B, still there is no consensus on the treatment of chronic hepatitis B. Tenofovir disoproxil fumarate show strong suppression of Hepatitis B virus with YMDD motif mutants and has a good safety record.
ACCESSION #
20279875

 

Related Articles

  • Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Wong, David K.H.; Cheung, Angela M.; O'Rourke, Keith; Naylor, C. David; Detsky, Allan S.; Heathcote, Jenny; Wong, D K; Cheung, A M; O'Rourke, K; Naylor, C D; Detsky, A S; Heathcote, J // Annals of Internal Medicine;8/15/93, Vol. 119 Issue 4, p312 

    Purpose: To determine whether alpha-interferon is effective in terminating viral replication and in eradicating the carrier state in patients with chronic hepatitis B virus (HBV) infection.Data Sources: Randomized controlled studies published in the English literature...

  • Genotype Mixtures of Hepatitis B Virus in Patients Treated with Interferon. Hannoun, Charles; Krogsgaard, Kim; Horal, Petr; Lindh, Magnus // Journal of Infectious Diseases;9/15/2002, Vol. 186 Issue 6, p752 

    Little is known about coinfection among several hepatitis B virus (HBV) genotypes, although previous reports of recombination and genotype shifts indicate that this should occur. In the present study, we designed a method to identify mixtures of genotype A and another genotype, regardless of...

  • Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon. Eto, Toshiharu; Takahashi, Hiroshi // Nature Medicine;May1999, Vol. 5 Issue 5, p577 

    Most chronic carriers of hepatitis D virus (HDV) do not respond to interferon (IFN) treatment. This limitation of IFN therapy may be due in part to scant expression of IFN receptor in the liver. Decause the asialoglycoprotein (ASGP) receptor is specifically expressed in the liver at high...

  • Immunosuppressants.  // Reactions Weekly;2/11/2012, Issue 1388, p19 

    The article describes the clinical cases of five patients who developed hepatitis B virus (HBV) reactivation after receiving immunosuppressant therapy.

  • HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B. Pawłowska, M.; Halota, W.; Smukalska, E.; Woźniakowska-Gęsicka, T.; Kupś, J. // European Journal of Clinical Microbiology & Infectious Diseases;Apr2012, Vol. 31 Issue 4, p571 

    The aim of this study was to assess HBV DNA suppression after 24 weeks of treatment with entecavir in previously treated children with CHB. Thirty children aged 5-17 years (25 males and 5 females) with CHB were treated with entecavir 0.5 or 1 mg daily. Twenty-two children were HBeAg-positive,...

  • Comparison of 12-Month Courses of Interferon-α -2b--Lamivudine Combination Therapy and Interferon-α -2b Monotherapy among Patients with Untreated Chronic Hepatitis B. Yalcin, Kendal; Degertekin, Halil; Yildiz, Fetin; Celik, Yusuf // Clinical Infectious Diseases;6/15/2003, Vol. 36 Issue 12, p1516 

    We compared the use of prolonged synchronous combination therapy with interferon (IFN)-α-2b and lami-vudine with the use of IFN-α-2b monotherapy in patients with untreated hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection. Thirty-three patients received...

  • Kinetics of Hepatitis B Virus Load During Haemodialysis Sessions and α-Interferon: A Prospective Study. Fabrizi, Fabrizio; Lunghi, Giovanna; alongi, Giancarlo; aucella, Filippo; Barbisoni, Francesco; Bisegna, Sergio; Mangano, Stefano; Romei-Longhena, Giorgio; artoni, andrea; Bettoni, Giuseppe; Messa, Piergiorgio; Martin, Paul // Kidney & Blood Pressure Research;Nov2013, Vol. 37 Issue 4/5, p286 

    Background: It has been reported a slow progression of hepatitis B in patients undergoing maintenance dialysis, and a role of dialysis session per se has been suggested. The aim of the present study is to evaluate the kinetics of the hepatitis B viral load (HBV DNA) in serum during haemodialysis...

  • An overview of treatment response rates to various anti-viral drugs in Pakistani Hepatitis B Virus infected patients. Ali, Liaqat; Idrees, Muhammad; Ali, Muhammad; Rehman, Irshad-ur; Hussain, Abrar; Afzal, Samia; Butt, Sadia; Saleem, Sana; Munir, Saira; Badar, Sadaf // Virology Journal;2011, Vol. 8 Issue 1, p1 

    Hepatitis B virus (HBV) is one of the leading health problem with up to 350 million affected people worldwide including 4.5 million only in Pakistan. It has mortality rate of 0.5 to 1.2 million per year worldwide. Pakistan lies in the endemic region with 3-5% HBV carrier rate in the country. The...

  • Reactivation of HBV with chemotherapy. Kemper, Carol A. // Infectious Disease Alert;Jul2012, Vol. 31 Issue 10, p118 

    The article discusses research being done on Hepatitis B virus (HBV) reactivation with chemotherapy which references the study "Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable," by ASF Lok, et al, in the 2012 issue of "Annals of Internal Medicine."

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics